<ul><li><span style="font-family:Arial, Helvetica, sans-serif;font-size:medium;">2QCY25: – EPS: PKR 2.79, PAT: PKR 968Mn, up 1.5x over the
SPLY.</span></li></ul><ul><li><span style="font-family:Arial, Helvetica, sans-serif;font-size:medium;">In 2QCY25, AGP’s topline is expected to clock-in at PKR
6.9Bn, up 20%YoY driven mainly by volumetric growth, the deregulation of non
essential medicines and higher prices for multiple essential medicines.
However, on a quarterly basis, we expect sales to decline ~4%QoQ primarily due
to seasonal effects that led to lower volumetric demand. Gross margins are
expected to arrive ~57%, up 2pptYoY, mainly due to the higher drug prices. On a
sequential basis, margins are likely to remain flat, as pricing gains are
offset by lower sales volumes.</span></li></ul><ul><li><span style="font-fa...
